Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old.~2. Medical record documentation of recurrent CDI per the study definition, that includes either: a) at least one recurrence after a primary episode and has completed at least one round of standard-of-care oral antibiotic therapy or b) has had at least two episodes of severe CDI resulting in hospitalization within the last year.~3. A positive stool test for the presence of toxigenic C. difficile within 30 days prior to or on the date of enrollment.~4. Is currently taking or was just prescribed antibiotics to control CDI related diarrhea at the time of enrollment.~\[Note: Subject's CDI diarrhea must be controlled (\<3 unformed/loose stools/day) while taking this course of antibiotics\]~Exclusion Criteria:~1. Currently has continued CDI diarrhea despite being on antibiotics prescribed for CDI treatment.~2. Previous fecal transplant~3. History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.~4. Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.~5. Compromised immune system (e.g. immunosuppressed due to a medical condition or medication; current or recent (\< 90 days) treatment with chemotherapy)~6. An absolute neutrophil count of \<1000 cells/µL during screening.~7. Pregnant, breastfeeding, or intends to become pregnant during study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is an suspension of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
- RBX2660 (Type: EXPERIMENTAL): RBX2660 is a rectally administered microbiota suspension in a 0.9% sodium chloride irrigation United States Pharmacopeia (USP) solution and cryoprotectant

Based on this trial design, predict the completion outcome and termination type (if applicable).